Please use this identifier to cite or link to this item: https://doi.org/10.1186/s12896-016-0285-6
DC FieldValue
dc.titleLarge-scale production of foot-and-mouth disease virus (serotype Asia1) VLP vaccine in Escherichia coli and protection potency evaluation in cattle
dc.contributor.authorXiao, Y
dc.contributor.authorChen, H.-Y
dc.contributor.authorWang, Y
dc.contributor.authorYin, B
dc.contributor.authorLv, C
dc.contributor.authorMo, X
dc.contributor.authorYan, H
dc.contributor.authorXuan, Y
dc.contributor.authorHuang, Y
dc.contributor.authorPang, W
dc.contributor.authorLi, X
dc.contributor.authorYuan, Y.A
dc.contributor.authorTian, K.
dc.date.accessioned2020-09-04T02:03:40Z
dc.date.available2020-09-04T02:03:40Z
dc.date.issued2016
dc.identifier.citationXiao, Y, Chen, H.-Y, Wang, Y, Yin, B, Lv, C, Mo, X, Yan, H, Xuan, Y, Huang, Y, Pang, W, Li, X, Yuan, Y.A, Tian, K. (2016). Large-scale production of foot-and-mouth disease virus (serotype Asia1) VLP vaccine in Escherichia coli and protection potency evaluation in cattle. BMC Biotechnology 16 (1) : 56. ScholarBank@NUS Repository. https://doi.org/10.1186/s12896-016-0285-6
dc.identifier.issn14726750
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/174251
dc.description.abstractBackground: Foot-and-mouth disease (FMD) is an acute, highly contagious disease that infects cloven-hoofed animals. Vaccination is an effective means of preventing and controlling FMD. Compared to conventional inactivated FMDV vaccines, the format of FMDV virus-like particles (VLPs) as a non-replicating particulate vaccine candidate is a promising alternative. Results: In this study, we have developed a co-expression system in E. coli, which drove the expression of FMDV capsid proteins (VP0, VP1, and VP3) in tandem by a single plasmid. The co-expressed FMDV capsid proteins (VP0, VP1, and VP3) were produced in large scale by fermentation at 10 L scale and the chromatographic purified capsid proteins were auto-assembled as VLPs in vitro. Cattle vaccinated with a single dose of the subunit vaccine, comprising in vitro assembled FMDV VLP and adjuvant, developed FMDV-specific antibody response (ELISA antibodies and neutralizing antibodies) with the persistent period of 6 months. Moreover, cattle vaccinated with the subunit vaccine showed the high protection potency with the 50 % bovine protective dose (PD50) reaching 11.75 PD50 per dose. Conclusions: Our data strongly suggest that in vitro assembled recombinant FMDV VLPs produced from E. coli could function as a potent FMDV vaccine candidate against FMDV Asia1 infection. Furthermore, the robust protein expression and purification approaches described here could lead to the development of industrial level large-scale production of E. coli-based VLPs against FMDV infections with different serotypes. © 2016 The Author(s).
dc.publisherBioMed Central Ltd.
dc.sourceUnpaywall 20200831
dc.subjectAntibodies
dc.subjectEscherichia coli
dc.subjectPurification
dc.subjectVaccines
dc.subjectViruses
dc.subjectE. coli
dc.subjectFifty percent protection dose (PD50)
dc.subjectFoot and mouth disease
dc.subjectSerotypes
dc.subjectVirus-like particles
dc.subjectDiseases
dc.subjectcapsid protein
dc.subjectfoot and mouth disease vaccine
dc.subjectimmunological adjuvant
dc.subjectneutralizing antibody
dc.subjectprotein VP0
dc.subjectprotein VP1
dc.subjectprotein VP3
dc.subjectunclassified drug
dc.subjectvirus like particle vaccine
dc.subjectrecombinant protein
dc.subjectvirus like particle vaccine
dc.subjectanimal experiment
dc.subjectantibody response
dc.subjectantibody specificity
dc.subjectArticle
dc.subjectbovine
dc.subjectchromatography
dc.subjectcontrolled study
dc.subjectdrug potency
dc.subjectenzyme linked immunosorbent assay
dc.subjectEscherichia coli
dc.subjectfermentation
dc.subjectfoot and mouth disease
dc.subjectFoot and mouth disease virus
dc.subjectgene expression system
dc.subjectnonhuman
dc.subjectprotein assembly
dc.subjectprotein purification
dc.subjectserotype
dc.subjectsingle drug dose
dc.subjectvaccination
dc.subjectanimal
dc.subjectbatch cell culture
dc.subjectbiosynthesis
dc.subjectCattle Diseases
dc.subjectFoot-and-Mouth Disease
dc.subjectgenetics
dc.subjectmetabolism
dc.subjectprocedures
dc.subjectprotein engineering
dc.subjectvirology
dc.subjectAnimals
dc.subjectBatch Cell Culture Techniques
dc.subjectCattle
dc.subjectCattle Diseases
dc.subjectEscherichia coli
dc.subjectFoot-and-Mouth Disease
dc.subjectProtein Engineering
dc.subjectRecombinant Proteins
dc.subjectVaccines, Virus-Like Particle
dc.typeArticle
dc.contributor.departmentBIOLOGY (NU)
dc.contributor.departmentDEPT OF BIOLOGICAL SCIENCES
dc.contributor.departmentMECHANOBIOLOGY INSTITUTE
dc.description.doi10.1186/s12896-016-0285-6
dc.description.sourcetitleBMC Biotechnology
dc.description.volume16
dc.description.issue1
dc.description.page56
dc.published.statePublished
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1186_s12896-016-0285-6.pdf1.45 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

28
checked on Nov 23, 2020

Page view(s)

20
checked on Nov 20, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.